11001 West 120th Avenue
About IM Therapeutics
IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen genes. The lead candidate drug is an oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. Our goal is to preserve pancreatic beta cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes.
Co-Founder and CEO: Steve Orndorff PhD
Scientific Co-Founder and CSO: Aaron Michels MD
Scientific Co-Founder and CMO: Peter Gottlieb MD
COO and CFO: Greg Kading
7 articles with IM Therapeutics
IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes
IM Therapeutics today announced positive results on safety, tolerability, pharmacokinetics (PK) and mechanistic action in a Phase 1b study of IMT-002 in patients with type 1 diabetes (T1D).
IM Therapeutics Co-Founder and CMO Peter Gottlieb, M.D, to Present Advances in Genetically Targeted Therapies for Type 1 Diabetes at the 2021 ADA Scientific Sessions
IM Therapeutics, Inc. announced today that Peter Gottlieb, M.D., Co-founder and Chief Medical Officer, will present at the American Diabetes Association (ADA) 81 st Scientific Sessions, held June 25-29, 2021.
IM Therapeutics, Inc., a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases, announced today that David Alleva, Ph.D., has joined its management team as Vice President, Immunology.
7/7/2020IM Therapeutics is developing a personalized, orally available small molecule therapeutic for diabetes. This is a milestone for autoimmune diseases and may be the first time diabetes patients can be preselected for a therapeutic based on whether they carry a specific gene.
ImmunoMolecular Therapeutics (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, today announced that it has raised $10 million in Series A financing to advance its novel HLA-targeted discovery platform and develop its lead drug candidate in type 1 diabetes (T1D).
ImmunoMolecular Therapeutics’ Scientific Co-founder Presents a Novel Small Molecule Approach to Blocking the Autoimmunity in Type 1 Diabetes
ImmunoMolecular Therapeutics today announced the presentation of a novel approach to blocking the autoimmunity in type 1 diabetes at the American Diabetes Association 78th Scientific Sessions.
ImmunoMolecular Therapeputics officially launched yesterday.